Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by skiboard09on Apr 02, 2021 2:15pm
199 Views
Post# 32932416

RE:RE:Great financials. Confusing call and roll out

RE:RE:Great financials. Confusing call and roll out

Biggest problem was the execution of what transpired yesterday. 

Apparently there was actually uploading issues with SEDAR. Confirmed by the BCSC. 


They just should of communicated better and maybe halted it till it got resolved. 


also the tots flip in roll out of Aristotle I think caught people off gaurd and this new LOI reminds people of Oncore deal which has produced NOTHING. 

I Like the whole treatment plan from beginning to end. But it will require huge marketing and on boarding. 


7 million isn't a huge number for a nationwide program. 


tripp also on the call was terrible and having our only Analyst mutter " I'm so disappointed " didn't help. 


tripp needs to communicate better period. 

see what Monday brings. 

<< Previous
Bullboard Posts
Next >>